Gabapentin Tablet, Coated
Product Images NDC 80425-0201

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 80425-0201). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Description (Description)

FDA Label Image

Fig 1 (Fig 1)

Fig 1 (Fig 1)
This is a chart that displays the mean pain scores over time for a 4-week dose titration period followed by a 4-week fixed dose period. The chart shows two groups: a placebo group and a group taking 3,600 mg/day of Gabapentin. The chart includes baseline and measurements at weeks 1-5 and 7-8.*
FDA Label Image

Label 1 (Lable 1)

Label 1 (Lable 1)
This is a description of Gabapentin medication which comes in the form of a 300mg tablet. This particular package contains 30 tablets with an NDC source number of 69367-0347-05 and NOC number of 80425020401. The lot number is S0GABBO1123 with a 111312053 expiration date. However, there is limited information in this text and it is unclear what the medication is used for.*
FDA Label Image

Label 2 (Lable 2)

Label 2 (Lable 2)
This is a description of a medication called Gabapentin. It comes in a form of a tablet with a strength of 500mg. The quantity is 60 tablets. The medication code is NDE 80425 0204-02. It has a lot number of 60GABBO001123 with an expiration date of 11/3/2023. The text also includes a unique identifier of S/ 000000115317.*
FDA Label Image

Fig 2 (Fig 2)

Fig 2 (Fig 2)
This is a chart indicating the mean pain score during a clinical trial for two different doses of gabapentin and a placebo. The trial consisted of a 3-week dose-iteration period followed by a 4-week fixed dose period. The chart shows the baseline score and scores at weeks 1-6. No other information or context is available.*
FDA Label Image

Fig 3 (Fig 3)

Fig 3 (Fig 3)
The given text seems to be a chart or a table showing some percentages, with headings like 100%, 90%, 80%, and so on. There are some blank spaces in between. The text also mentions two studies (Study 1 and Study 2) with some percentages, and some abbreviations like PBO. The text does not provide any context or information about what these numbers and abbreviations represent, making it not possible to provide a useful description.*
FDA Label Image

Fig 4 (Fig 4)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.